DC-OPEN-GOVT-PARTNERSHIP
13.12.2021 10:02:14 CET | Business Wire | Press release
Days after the White House Summit for Democracy, thousands in the open government community will gather for the Open Government Partnership (OGP) Global Summit in Seoul, Republic of Korea on December 15-17. The participants, including a dozen Heads of State and hundreds of civil society leaders, will focus on how reformers in and out of government can work together to advance democratic reforms and fight growing authoritarianism.
The Global Summit comes as democracies continue to face internal and external threats. The state of democracy, as measured by Freedom House , is at its weakest in 15 years, and more than a quarter of the world’s population now lives in democratically backsliding countries.
“Across our Partnership, courageous reformers are advancing ambitious reforms to renew democracy and tackle unprecedented global crises—from a devastating pandemic to economies in turmoil. Our platform also seeks to ensure that commitments made at high-level events such as last week’s White House Summit for Democracy and COP26 are turned into concrete actions,” said Sanjay Pradhan, Chief Executive Officer of OGP .
At the OGP Summit, U.S. President Joseph Biden is expected to urge nations to take up a call to action to “fight the scourge of corruption” by working in partnership with civil societies and courageous citizens around the world.
According to OGP’s Civil Society Co-Chair María Baron , “Government and civil society can work together when they share the same mission, even if approaches and perspectives differ. To counter the global issues we face, we must act collectively. While OGP has one of the most vibrant communities of civil society organizations and activists, we cannot do it without government.”
This year, OGP celebrates its 10th anniversary. At the Summit, it will release an in-depth Decade Report, featuring stories and analysis of independent data showing that when governments co-create reforms with civil society, they are more ambitious and results are stronger. More than 4,500 reforms have been co-created in 78 countries over the past decade. 2,000 of these were reviewed independently, and over 20 percent were assessed to have made government significantly more open. The report also found that countries that used their OGP action plan to fight corruption were more likely to carry out reforms.
These actions help fight corruption, promote direct citizen engagement, combat growing inequality, and improve citizen trust of government. For example:
- Data shows that the more open a government is, the better the socio-economic outcomes .
- Countries that published more government data have had lower death rates during COVID-19 than more secretive governments.
- Countries that have more budget transparency borrow money at lower rates and spend more of it on vital social services.
Since 2011, the Open Government Partnership, founded by eight national members and nine civil society organizations and initiated by former U.S. President Barack Obama , has grown into a partnership of 78 national and 76 local government members and thousands of civil society organizations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211213005121/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
